

Poonawalla Fincorp Limited (Revised)

March 12, 2024

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long-term bank facilities	12,655.65	CARE AAA; Stable	Reaffirmed
Long-term / Short-term bank facilities	344.35	CARE AAA; Stable / CARE A1+	Reaffirmed
Short-term bank facilities	200.00	CARE A1+	Reaffirmed
Perpetual debt	79.10	CARE AA+; Stable	Reaffirmed
Subordinate debt	230.00	CARE AAA; Stable	Reaffirmed
Market-linked debentures	250.00	CARE PP-MLD AAA; Stable	Reaffirmed
Non-convertible debentures	4,440.90	CARE AAA; Stable	Reaffirmed
Commercial paper	6,500.00 (Enhanced from 6,000.00)	CARE A1+	Reaffirmed

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

CARE Ratings Limited (CARE Ratings) has reaffirmed the ratings of the various long-term and short-term facilities of Poonawalla Fincorp Limited (PFL).

The ratings continue to reflect the expectation of strong support from the Cyrus Poonawalla group and the healthy financial flexibility of the group to provide this support. This is derived from the fact that the promoter, i.e., the Cyrus Poonawalla group holds 62.07% stake through its core investment company (CIC) – Rising Sun Holdings Private Limited (RSHPL; rated 'CARE AAA Stable'), with Mr Adar Poonawalla as the Chairman of the board. Furthermore, during FY21 and FY22, the group's flagship company, Serum Institute of India Private Ltd (SI IPL; rated 'CARE AAA; Stable/CARE A1+') invested around ₹5,000 crore in RSHPL through compulsorily convertible cumulative preference shares (CCPS). This capital was used to infuse funds in various businesses of the group, including PFL, with RSHPL making an equity infusion of ₹3,206 crore in PFL in May 2021. This sizeable investment made in the acquisition of PFL reflects the strategic importance of the financial services business to the group and the expectation of timely need-based financial support. The significant infusion of equity capital resulted in a comfortable capital adequacy ratio (CAR) and low leverage. Furthermore, given the strong association with the Cyrus Poonawalla group, PFL has been able to raise incremental funds at competitive rates in the debt market, reflecting the market perception of the strong group support.

The ratings also continue to factor in the change in the name from 'Magma' to 'Poonawalla', which is the family name of the promoters, creating a strong moral obligation to support PFL. The rating also considers the stability in the senior management team consisting of seasoned professionals and the revised product strategy targeting better-quality retail consumers and micro, small and medium enterprise (MSME) businesses in urban and semi urban locations, credit tested with a higher CIBIL and downsizing the low value-added businesses.

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

There has been an improvement in the overall resource base with borrowings at competitive rates; an improvement in the asset quality and sufficient provisioning to cover from any major shocks, along with sequential improvement in the profitability. PFL's well-diversified loan book coupled with increased focus on risk management, aggressive write-off policy and digitization is expected to enable it to efficiently manage its asset quality going forward.

The Cyrus Poonawalla group is one of the leading players in the pharmaceuticals and biotechnology segments. The group's flagship company, SIIPL (rated 'CARE AAA; Stable/CARE A1+'), is one of the world's largest manufacturers of measles and DTP vaccines. The group has also set up Serum Institute Life Sciences Private Ltd (SLS; rated 'CARE AAA; Stable/CARE A1+') to fulfil its adequate response to COVID-19. SIIPL has diverse product offerings in the vaccine segment, including the COVID-19 vaccine 'Covishield'.

The ratings also consider the relatively modest assets under management (AUM) of ₹21,946 crore (standalone) as on December 31, 2023, as against ₹ 16,143 crore as on March 31, 2023 (FY22: ₹11,765 crore). The ability of the company to profitably scale up the business with new product lines while maintaining the asset quality remains monitorable. Furthermore, the parentage and strategic importance to the group, its overall gearing, asset quality and profitability are the key rating sensitivities.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

Not applicable.

Negative factors

- Weakening of the linkages with the parent group, promoter group or promoter family.
- Overall gearing exceeding 3.5-4x on a sustained basis.
- Deterioration in the asset quality parameters such that the net non-performing assets (NNPA) remain above 2%.
- Decline in profitability with the return on total assets (ROTA) declining below 2%.

Analytical approach:

CARE Ratings Limited (CARE Ratings) has evaluated the standalone credit risk profile of PFL factoring in the linkages with the parent i.e., Rising Sun Holdings Private Limited (RSHPL; rated 'CARE AAA; Stable'). The ratings continue to factor in the expectation of need-based timely support to PFL from the Cyrus Poonawalla group, whose flagship company is Serum Institute of India Private Limited (SIIPL, rated; 'CARE AAA/Stable/CARE A1+').

Outlook: Stable/Positive/Negative

CARE Ratings believes that PFL will continue to demonstrate a stable business profile with the expectation of need-based timely support from the Cyrus Poonawalla group, whose flagship company is Serum Institute of India Private Limited, given the high strategic importance, the shared brand name and the management control.

Detailed description of the key rating drivers:

Key strengths

Strong and resourceful promoter

The Cyrus Poonawalla group holds 62.07% (as on December 2023) stake in PFL through RSHPL. RSHPL is the CIC of the group, having investments in insurance, retail, pharma, and the financial services segments. During FY21 and FY22, the group's flagship company, SIIPL, invested ₹5,000 crore in RSHPL through CCPS. This capital was used to infuse funds in various businesses of the group, including PFL, with RSHPL making an equity infusion of ₹3,206 crore in PFL in May 2021.

Additionally, PFL is strategically important to the group, as indicated by the sharing of the 'Poonawalla' name, Mr Adar Poonawalla being the Chairman of the board, and the large investment made by the group to diversify into the financial services segment with the acquisition of the retail lending of the erstwhile Magma.

The Cyrus Poonawalla group is one of India's reputed business houses and is a leading player in the pharmaceuticals and biotechnology segments. The group's flagship company, SIIPL, is one of the world's largest manufacturers of vaccines, supplying to around 170 countries. SIIPL has a robust financial profile with a total operating income (TOI) of ₹10,190 crore with a profit-after-tax (PAT) of ₹4,187 crore in FY23. The net worth stood at ₹36,815 crore as on March 31, 2023.

SIIPL has a healthy liquid investment portfolio to the tune of ₹5,404 crore along with cash and bank balance of ₹733 crore as on March 31, 2023. Furthermore, SIIPL generated strong cash accruals of ₹4,900 crore during FY23 and is expected to generate cash accruals in the range of ₹4,000-4,500 crore every year in the medium term. Thus, the group has a robust financial profile with healthy cash accruals and minimal debt obligations.

Experienced senior management

PFL is being led by Mr. Adar Poonawalla as the Chairman and Non-Executive Director of the board along with a team of seasoned professionals having specialization in the financial services business with a track record of successful market leadership, which are stable at all levels.

As on March 31, 2023, the company is governed by a 10-member board of directors, including five independent directors. The board comprises qualified and experienced professionals with considerable experience in functional areas. The board is ably supported by a qualified senior management team, led by Mr Abhay Bhutada, Managing Director, who is a seasoned finance professional with over 15 years of diversified experience in the commercial and retail lending domain. He is driving the digitisation initiatives for the company and has been instrumental in setting up the initial foray into the retail lending business for the group.

Focused and diversified product approach in the retail segment

The new management's business plan revolves around a revised product strategy, targeting credit-tested, better-quality retail consumers and MSME businesses in urban and semi-urban locations. Professional management and strong financial flexibility will be the key enablers for PFL's product strategy. PFL plans to achieve a 3x growth (over FY21) in AUM by FY25 with a focused product approach consisting of a mix of unsecured (digital personal loans, digital loans to professionals, digital business loans, merchant cash advance, supply chain finance) and secured products (pre-owned car loans, loan-against property [LAP], digital consumer finance, machinery and medical equipment loans) products. As part of the new business strategy, PFL has also discontinued products like tractors, commercial vehicles (CVs), construction equipment (CE), and new cars for business and operational efficiency. The AUM as on December 31, 2023, stood at ₹ 21,946 crore, of which the discontinued products constitute 1.7% of the total portfolio which is expected to run down completely. PFL plans to achieve operating efficiencies through the increasing use of technology and digitalization. PFL uses the branchless digital model for its unsecured loan products, enabling deeper customer reach, and aiding scalability with diversification. PFL has an end-to-end technology-enabled process, covering origination, underwriting, analytics, credit policies, disbursals, collections, and recovery.

Improved access to funding

With a strong parent coupled with a strong management team, the company has wider access to a more diversified liability market along with a significant reduction in the cost of funds. The company has received fresh sanctions at much lower rates of interest and has replaced the entire re-priceable high-cost legacy debt. The same has witnessed a consistent decline since the acquisition by the Cyrus Poonawalla group. The company has diversified its funding sources, including the access to capital markets, in addition to diversified bank funding, by the introduction of more private sector banks and foreign banks.

Low leverage and diversified resource profile

The company has a diversified resource profile in terms of the mix of bank and debt capital markets borrowings. PFL's standalone borrowings as on December 31, 2023, was in the form of 49% term loans, 30% cash credit and working capital demand loans, 14% commercial papers (CPs), 6% non-convertible debentures (NCDs), and 1% perpetual and sub-debt. Moreover, the overall gearing continues to remain lower at 1.57x as on December 31, 2023. Furthermore, as part of the stake sale of the housing subsidiary, PHFL, PFL has received ₹ 2,966 crore as post-tax consideration, which has enhanced the capital position of the company. With the improving scale of operations, CARE Ratings expects the gearing to increase.

The resource profile has seen improvement since March 2021 and the company has increased its lender base by onboarding private and foreign banks and has commenced capital market borrowings by tapping the CP market and issuing NCDs. The company is expected to be able to leverage and raise further debt capital to embark on a growth plan envisaged by the management to take its AUM to around the 3x (over FY21) level by FY25. The diversification of the resource profile with increasing relationships across various categories of banks and capital market investors has resulted in a stable liability profile. Furthermore, the liquidity of ₹ 2,986 crore (including the unutilized lines of ₹ 1,750 crore) is available as on January 31, 2024.

Improved asset quality with adequate provisioning and aggressive write-off policy.

The GNPA/GS3 and NNPA/NS3 assets, as a percentage of advances, improved to 1.33% and 0.70% respectively as on December 31, 2023 (1.44% and 0.78% respectively as on March 31, 2023) as against 3.29% and 1.30%, respectively, as on March 31, 2022.

With the new management taking over control in May 2021, the company has remodelled its underwriting practices and implemented an aggressive write-off and provision coverage policy. The improvement was also on account of the low non-performing assets (NPAs) being reported in the new product segments. The new management has realigned the product mix of the company with greater focus on better quality, credit tested, higher CIBIL and better credit worthiness in urban and semi-urban geographies, along with discontinuation of some erstwhile products. The product strategy is primarily aimed at minimizing the credit costs in future and focusing on products with digital collections. Furthermore, the Stage III provision coverage was healthy at 47.33% as Dec 31, 2023.

Key weaknesses**Moderate scale of operations, and market position**

As on December 2023, PFL's standalone AUM stood at ₹21,946 crore (₹ 16,143 crore as on March 31, 2023) as compared with ₹11,765 crore as on March 31, 2022. The AUM is spread across multiple asset classes which gives PFL the benefit of diversity, however the scale of operations and market position remains moderate within each asset class. PFL has, however, reported growth in each asset class quarter-on-quarter.

Furthermore, the standalone profit after tax stood at ₹1,724 crore (post exceptional item) for 9MFY24. The company's standalone profit after tax stood at ₹585 crore for FY23 (₹293 crore for FY22) resulting in a ROTA for FY23 of 3.79%. The improvement in profitability is on account of the improved funding costs resulting in improved margins supported by a reduction in credit costs.

However, the ability of the company to improve its market position and manage the credit costs will remain a key monitorable.

New product segments

As a part of the new business strategy, the management has forayed into new product lines and has discontinued products like tractors, commercial vehicles (CVs), construction equipment (CE), and new cars for business and operational efficiency. Going forward, the management will focus on a mix of unsecured products (digital personal loans, digital loans to professionals, digital business loans, digital consumer finance, merchant cash advance, supply chain finance) and secured products (pre-owned car loans, loan-against property [LAP], machinery and medical equipment loans).

PFL has got the approval of Co-branded credit card from the regulator. Going forward, the company's secured to unsecured product mix is expected to be in the ratio of 50:50. (currently 52:48)

The company's ability to profitably scale up its portfolio across diverse segments remains a key monitorable.

Liquidity: Strong

As on December 31, 2023, the asset liability maturity (ALM) profile of PFL shows a significant surplus position across all the time buckets, aided by a large equity base, lower debt level, and inherently short-to-medium duration of assets. With RSHPL now being the largest shareholder, the financial flexibility is improved significantly. On a standalone basis, PFL had a strong liquidity of ₹2,986 crore (including undrawn lines of ₹1,750 crore) as on January 31, 2024.

Environment, social, and governance (ESG) risks

PFL maintains adequate transparency in its business ethics practices as can be inferred from the entity's disclosures regarding its grievance redressal, related party transactions, fair practice code, whistle blower policy and prevention of sexual harassment policy. The board comprises of ten directors, of which there is one female director; further, there are five independent directors. The entity has the necessary Audit Committee, Nomination and Remuneration committee and Corporate Social Responsibility (CSR) committee in place. The company is also governed by an Information Technology framework as recommended by RBI. PFL has constituted an ESG Committee, and it reports to the board. PFL continues to work on several community development initiatives through its CSR projects.

Applicable criteria

[Definition of Default](#)

[Rating Outlook and Rating Watch](#)

[Financial Ratios - Financial Sector](#)

[Short Term Instruments](#)

[Non Banking Financial Companies](#)

[Market Linked Notes](#)

[Factoring Linkages Parent Sub JV Group](#)

About the company and industry

Industry classification

Macro-economic indicator	Sector	Industry	Basic industry
Financial Services	Financial Services	Finance	Non Banking Financial Company (NBFC)

PFL is a non-deposit-taking systemically important non-banking finance company (NBFC) registered with the Reserve Bank of India (RBI). Incorporated as Magma Leasing Limited, the company entered the financing business in 1989. It was renamed MFL in 2008 and PFL in 2021, post-acquisition of the controlling stake of 60% by RSHPL (the entity owned and controlled by Mr Adar Poonawalla). PFL has various product offerings in the consumer and small business finance segments, including digital personal loans, pre-owned car loans, digital business loans, LAP. It operates through a network of 103 branches as on December 31, 2023, across 19 states of India.

Brief Financials (₹ crore)- Standalone	FY22/March 31, 2022 (A)	FY23/ March 31, 2023 (A)	9MFY24/Dec 31, 2023 (UA)#
Total income	1,567	2,010	2,230
PAT	293	585	1,724*
Overall gearing (times)	1.22	1.75	1.57
Total Assets	12,810	18,022	-
Net NPA (%)	1.30	0.78	0.70
ROTA (%)	2.53	3.79	-

A: Audited; UA: Unaudited; Note: 'The above results are latest financial results available.'

Ratios: As per CARE Ratings' calculations.

*Post exceptional item

#Not Annualised

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for the last three years: Please refer to Annexure-2

Covenants of the rated instruments / facilities: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of the various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Cash Credit	-	-	-	-	3,823.50	CARE AAA; Stable
Fund-based-Term loan-Long term	-	-	-	Sept 2029	7,119.28	CARE AAA; Stable

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund based - Term loan - Long term (Proposed)	-	-	-	-	148.20	CARE AAA; Stable
Fund based – Long term	-	-	-	Sept 2029	1,166.33	CARE AAA; Stable
Fund based – Long term (Proposed)	-	-	-	-	398.34	CARE AAA; Stable
Non-fund-based - LT/ ST-BG/LC	-	-	-	-	344.35	CARE AAA; Stable / CARE A1+
Fund-based - ST-Working Capital Limits-Proposed	-	-	-	-	200.00	CARE A1+
Debt-Perpetual Debt	INE511C08928	18-Sep-15	12.10%	NA	2.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08936	15-Oct-15	12.10%	NA	5.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08944	14-Jun-16	12.10%	NA	3.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08951	05-Jul-16	12.10%	NA	1.70	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08969	01-Aug-16	12.10%	NA	10.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08977	09-Sep-16	12.10%	NA	3.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08AF8	03-Feb-17	11.50%	NA	1.90	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08AH4	07-Mar-17	11.50%	NA	1.00	CARE AA+; Stable
Debt-Perpetual Debt	INE511C08AJ0	04-Aug-17	11.00%	NA	1.00	CARE AA+; Stable
Debt-Perpetual Debt-Proposed	-	-	-	-	50.50	CARE AA+; Stable
Debt- Subordinate Debt	INE511C08985	07-Dec-16	10.40%	07-Dec-26	35.00	CARE AAA; Stable
Debt- Subordinate Debt	INE511C08AD3	06-Jan-17	10.40%	06-Jan-27	15.00	CARE AAA; Stable
Debt- Subordinate Debt	INE511C08AE1	24-Jan-17	10.40%	24-Jan-27	25.00	CARE AAA; Stable

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Debt- Subordinate Debt	INE511C08AG6	03-Mar-17	10.25%	03-Mar-27	15.00	CARE AAA; Stable
Debt- Subordinate Debt	INE511C08AI2	18-May-17	10.10%	18-May-27	10.00	CARE AAA; Stable
Debt- Subordinate Debt	INE511C08AK8	07-Mar-18	10.20%	06-Jun-25	5.00	CARE AAA; Stable
Debt- Subordinate Debt	INE511C08AL6	28-Mar-18	10.00%	28-Mar-28	5.00	CARE AAA; Stable
Debt-Subordinate Debt-Proposed	-	-	-	-	120.00	CARE AAA; Stable
Debentures-Market Linked Debentures	INE511C07771	25-Jan-23	Market Linked - 7.80%	23-Jan-26	100.00	CARE PP-MLD AAA; Stable
Debentures-Market Linked Debentures-Proposed	-	-	-	-	150.00	CARE PP-MLD AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07672	06-May-19	10.04%	06-May-24	6.17	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07680	06-May-19	10.50%	06-May-24	77.82	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07698	06-May-19	Zero Coupon	06-May-24	1.19	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07706	06-May-19	10.27%	06-May-29	2.67	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07714	06-May-19	10.75%	06-May-29	2.03	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07599	06-Apr-17	9.00%	06-Apr-24	50.00	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07789	27-Feb-23	8.10% - (Floater)	27-Feb-26	100.00	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07805	07-Feb-24	8.38%	06-Feb-26	250.00	CARE AAA; Stable
Debentures-Non-Convertible Debentures	INE511C07797	07-Feb-24	8.38%	27-Feb-26	250.00	CARE AAA; Stable
Debentures- Non-Convertible Debentures-Proposed	-	-	-	-	3,701.01	CARE AAA; Stable
Commercial Paper	INE511C14VY3	28-Dec-23	7.90%	27-Mar-24	100.00	CARE A1+

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Commercial Paper	INE511C14VY3	29-Dec-23	7.90%	27-Mar-24	100.00	CARE A1+
Commercial Paper	INE511C14VZ0	03-Jan-24	7.95%	19-Mar-24	150.00	CARE A1+
Commercial Paper	INE511C14WA1	05-Jan-24	8.00%	18-Mar-24	250.00	CARE A1+
Commercial Paper	INE511C14WB9	16-Jan-24	7.75%	22-Mar-24	300.00	CARE A1+
Commercial Paper	INE511C14WC7	02-Feb-24	8.78%	03-May-24	250	CARE A1+
Commercial Paper	INE511C14WC7	02-Feb-24	8.75%	03-May-24	200	CARE A1+
Commercial Paper	INE511C14WD5	06-Feb-24	8.78%	07-May-24	250	CARE A1+
Commercial Paper	INE511C14WD5	06-Feb-24	8.75%	07-May-24	250	CARE A1+
Commercial Paper	INE511C14WE3	09-Feb-24	8.60%	10-May-24	250	CARE A1+
Commercial Paper	INE511C14WF0	20-Feb-24	8.60%	20-May-24	250	CARE A1+
Commercial Paper	INE511C14WG8	23-Feb-24	8.50%	24-May-24	250	CARE A1+
Commercial Paper	INE511C14WH6	28-Feb-24	8.40%	29-May-24	150	CARE A1+
Commercial Paper	INE511C14WI4	06-Mar-24	8.30%	05-June-24	150	CARE A1+
Commercial Paper (Proposed)	-	-	-	-	3,600.00	CARE A1+

Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021

					in 2023-2024			
1	Debt-Perpetual Debt	LT	-	-	-	-	-	1)Withdrawn (16-Feb-21) 2)CARE A+; Negative (03-Jul-20) 3)CARE A+; Negative (28-Apr-20)
2	Commercial Paper-Commercial Paper (Standalone)	ST	6500.00	CARE A1+	1)CARE A1+ (09-Oct-23) 2)CARE A1+ (12-Sep-23) 3)CARE A1+ (18-Jul-23)	1)CARE A1+ (26-Dec-22) 2)CARE A1+ (30-Sep-22) 3)CARE A1+ (01-Aug-22)	1)CARE A1+ (11-Nov-21) 2)CARE A1+ (23-Sep-21) 3)CARE A1+ (26-Aug-21) 4)CARE A1+ (13-Apr-21)	1)CARE A1+ (16-Feb-21) 2)CARE A1+ (03-Jul-20) 3)CARE A1+ (28-Apr-20)
3	Debt-Subordinate Debt	LT	-	-	-	-	1)Withdrawn (26-Aug-21)	1)CARE AA-(CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
4	Debt-Perpetual Debt	LT	-	-	-	-	-	1)Withdrawn (16-Feb-21)

								2)CARE A+; Negative (03-Jul-20) 3)CARE A+; Negative (28-Apr-20)
5	Debt-Perpetual Debt	LT	25.00	CARE AA+; Stable	1)CARE AA+; Stable (09-Oct- 23) 2)CARE AA+; Stable (12-Sep- 23) 3)CARE AA+; Stable (18-Jul- 23)	1)CARE AA+; Stable (26-Dec-22) 2)CARE AA+; Stable (30-Sep-22) 3)CARE AA; Stable (01-Aug-22)	1)CARE AA; Stable (11-Nov-21) 2)CARE AA; Stable (23-Sep-21) 3)CARE AA; Stable (26-Aug-21)	1)CARE A+ (CW with Developing Implications) (16-Feb-21) 2)CARE A+; Negative (03-Jul-20) 3)CARE A+; Negative (28-Apr-20)
6	Fund-based - LT- Cash Credit	LT	3823.50	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct- 23) 2)CARE AAA; Stable (12-Sep- 23) 3)CARE AAA; Stable (18-Jul- 23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)

7	Term Loan-Long Term	LT	7267.48	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
8	Non-fund-based - LT/ ST-BG/LC	LT/ST	344.35	CARE AAA; Stable / CARE A1+	1)CARE AAA; Stable / CARE A1+ (09-Oct-23) 2)CARE AAA; Stable / CARE A1+ (12-Sep-23) 3)CARE AAA; Stable / CARE A1+ (18-Jul-23)	1)CARE AAA; Stable / CARE A1+ (26-Dec-22) 2)CARE AAA; Stable / CARE A1+ (30-Sep-22) 3)CARE AA+; Stable / CARE A1+ (01-Aug-22)	1)CARE AA+; Stable / CARE A1+ (11-Nov-21) 2)CARE AA+; Stable / CARE A1+ (23-Sep-21) 3)CARE AA+; Stable / CARE A1+ (26-Aug-21)	1)CARE AA- / CARE A1+ (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative / CARE A1+ (03-Jul-20) 3)CARE AA-; Negative / CARE A1+ (28-Apr-20)
9	Commercial Paper- Commercial Paper (Carved out)	ST	-	-	-	-	-	1)Withdrawn (28-Apr-20)
10	Debt-Subordinate Debt	LT	20.00	CARE AAA; Stable	1)CARE AAA; Stable	1)CARE AAA; Stable (26-Dec-22)	1)CARE AA+; Stable (11-Nov-21)	1)CARE AA- (CW with

					(09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
11	Debt-Subordinate Debt	LT	15.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
12	Debt-Subordinate Debt	LT	48.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative

					3)CARE AAA; Stable (18-Jul-23)			(28-Apr-20)
13	Debt-Perpetual Debt	LT	10.90	CARE AA+; Stable	1)CARE AA+; Stable (09-Oct-23) 2)CARE AA+; Stable (12-Sep-23) 3)CARE AA+; Stable (18-Jul-23)	1)CARE AA+; Stable (26-Dec-22) 2)CARE AA+; Stable (30-Sep-22) 3)CARE AA; Stable (01-Aug-22)	1)CARE AA; Stable (11-Nov-21) 2)CARE AA; Stable (23-Sep-21) 3)CARE AA; Stable (26-Aug-21)	1)CARE A+ (CW with Developing Implications) (16-Feb-21) 2)CARE A+; Negative (03-Jul-20) 3)CARE A+; Negative (28-Apr-20)
14	Debt-Subordinate Debt	LT	-	-	-	-	-	1)Withdrawn (28-Apr-20)
15	Debt-Subordinate Debt	LT	14.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
16	Debt-Perpetual Debt	LT	-	-	-	-	-	1)Withdrawn (28-Apr-20)

17	Debentures-Non Convertible Debentures	LT	30.90	CARE AAA; Stable	<p>1)CARE AAA; Stable (09-Oct-23)</p> <p>2)CARE AAA; Stable (12-Sep-23)</p> <p>3)CARE AAA; Stable (18-Jul-23)</p>	<p>1)CARE AAA; Stable (26-Dec-22)</p> <p>2)CARE AAA; Stable (30-Sep-22)</p> <p>3)CARE AA+; Stable (01-Aug-22)</p>	<p>1)CARE AA+; Stable (11-Nov-21)</p> <p>2)CARE AA+; Stable (23-Sep-21)</p> <p>3)CARE AA+; Stable (26-Aug-21)</p>	<p>1)CARE AA- (CW with Developing Implications) (16-Feb-21)</p> <p>2)CARE AA-; Negative (03-Jul-20)</p> <p>3)CARE AA-; Negative (28-Apr-20)</p>
18	Debt-Subordinate Debt	LT	-	-	-	-	<p>1)Withdrawn (26-Aug-21)</p>	<p>1)CARE AA- (CW with Developing Implications) (16-Feb-21)</p> <p>2)CARE AA-; Negative (03-Jul-20)</p> <p>3)CARE AA-; Negative (28-Apr-20)</p>
19	Debt-Perpetual Debt	LT	25.50	CARE AA+; Stable	<p>1)CARE AA+; Stable (09-Oct-23)</p> <p>2)CARE AA+; Stable (12-Sep-23)</p>	<p>1)CARE AA+; Stable (26-Dec-22)</p> <p>2)CARE AA+; Stable (30-Sep-22)</p> <p>3)CARE AA; Stable (01-Aug-22)</p>	<p>1)CARE AA; Stable (11-Nov-21)</p> <p>2)CARE AA; Stable (23-Sep-21)</p> <p>3)CARE AA; Stable (26-Aug-21)</p>	<p>1)CARE A+ (CW with Developing Implications) (16-Feb-21)</p> <p>2)CARE A+; Negative (03-Jul-20)</p> <p>3)CARE A+; Negative (28-Apr-20)</p>

					3)CARE AA+; Stable (18-Jul-23)			
20	Debt-Subordinate Debt	LT	-	-	-	-	1)Withdrawn (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
21	Debt-Subordinate Debt	LT	-	-	-	-	1)Withdrawn (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
22	Debt-Subordinate Debt	LT	50.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative

					3)CARE AAA; Stable (18-Jul-23)			(28-Apr-20)
23	Debentures-Non Convertible Debentures	LT	164.80	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
24	Debt-Subordinate Debt	LT	-	-	-	-	-	1)Withdrawn (28-Apr-20)
25	Debt-Subordinate Debt	LT	-	-	-	-	-	1)Withdrawn (28-Apr-20)
26	Debt-Perpetual Debt	LT	-	-	-	-	-	1)Withdrawn (28-Apr-20)
27	Debentures-Non Convertible Debentures	LT	50.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)

					(18-Jul-23)			
28	Debentures-Non Convertible Debentures	LT	50.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
29	Debentures-Non Convertible Debentures	LT	-	-	-	1)Withdrawn (30-Sep-22) 2)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20) 3)CARE AA-; Negative (28-Apr-20)
30	Debentures-Non Convertible Debentures	LT	4055.32	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21) 2)CARE AA-; Negative (03-Jul-20)

					3)CARE AAA; Stable (18-Jul- 23)			
31	Debentures-Non Convertible Debentures	LT	-	-	-	1)Withdrawn (30-Sep-22) 2)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	1)CARE AA- (CW with Developing Implications) (16-Feb-21)
32	Fund-based-Long Term	LT	1564.67	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct- 23) 2)CARE AAA; Stable (12-Sep- 23) 3)CARE AAA; Stable (18-Jul- 23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21) 2)CARE AA+; Stable (23-Sep-21) 3)CARE AA+; Stable (26-Aug-21)	-
33	Fund-based - ST- Working Capital Limits	ST	200.00	CARE A1+	1)CARE A1+ (09-Oct- 23) 2)CARE A1+ (12-Sep- 23)	1)CARE A1+ (26-Dec-22) 2)CARE A1+ (30-Sep-22) 3)CARE A1+ (01-Aug-22)	1)CARE A1+ (11-Nov-21) 2)CARE A1+ (23-Sep-21) 3)CARE A1+ (26-Aug-21)	-

					3)CARE A1+ (18-Jul-23)			
34	Debentures-Non Convertible Debentures	LT	-	-	-	1)Withdrawn (30-Sep-22) 2)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
35	Debentures-Non Convertible Debentures	LT	-	-	-	1)Withdrawn (30-Sep-22) 2)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
36	Debentures-Non Convertible Debentures	LT	6.17	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
37	Debentures-Non Convertible Debentures	LT	77.82	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22)	1)CARE AA+; Stable (11-Nov-21)	-

					(12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	3)CARE AA+; Stable (01-Aug-22)		
38	Debentures-Non Convertible Debentures	LT	1.19	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
39	Debentures-Non Convertible Debentures	LT	2.67	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-

40	Debentures-Non Convertible Debentures	LT	2.03	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
41	Debt-Subordinate Debt	LT	83.00	CARE AAA; Stable	1)CARE AAA; Stable (09-Oct-23) 2)CARE AAA; Stable (12-Sep-23) 3)CARE AAA; Stable (18-Jul-23)	1)CARE AAA; Stable (26-Dec-22) 2)CARE AAA; Stable (30-Sep-22) 3)CARE AA+; Stable (01-Aug-22)	1)CARE AA+; Stable (11-Nov-21)	-
42	Debt-Perpetual Debt	LT	17.70	CARE AA+; Stable	1)CARE AA+; Stable (09-Oct-23) 2)CARE AA+; Stable	1)CARE AA+; Stable (26-Dec-22) 2)CARE AA+; Stable (30-Sep-22)	1)CARE AA; Stable (11-Nov-21)	-

					(12-Sep-23) 3)CARE AA+; Stable (18-Jul-23)	3)CARE AA; Stable (01-Aug-22)		
43	Debentures-Market Linked Debentures	LT	250.00	CARE PP-MLD AAA; Stable	1)CARE PP-MLD AAA; Stable (09-Oct-23) 2)CARE PP-MLD AAA; Stable (12-Sep-23) 3)CARE PP-MLD AAA; Stable (18-Jul-23)	1)CARE PP-MLD AAA; Stable (26-Dec-22) 2)CARE PP-MLD AAA; Stable (30-Sep-22) 3)CARE PP-MLD AA+; Stable (01-Aug-22)	-	-

LT: Long term; ST: Short term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities

Not applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Commercial Paper-Commercial Paper (Standalone)	Simple
2	Debentures-Market Linked Debentures	Highly Complex
3	Debentures-Non Convertible Debentures	Simple

Sr. No.	Name of the Instrument	Complexity Level
4	Debt-Perpetual Debt	Highly Complex
5	Debt-Subordinate Debt	Complex
6	Debt-Subordinate Debt	Simple
7	Fund-based - LT-Cash Credit	Simple
8	Fund-based - ST-Working Capital Limits	Simple
9	Fund-based-Long Term	Simple
10	Non-fund-based - LT/ ST-BG/LC	Simple
11	Term Loan-Long Term	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please [click here](#)

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact Us**Media Contact**

Mradul Mishra

Director

CARE Ratings Limited

Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in**Relationship Contact**

Pradeep Kumar V

Senior Director

CARE Ratings Limited

Phone: 91 44 2850 1001

E-mail: pradeep.kumar@careedge.in**Analytical Contacts**

Sanjay Agarwal

Senior Director

CARE Ratings Limited

Phone: 022-6754 3500

E-mail: sanjay.agarwal@careedge.in

Gaurav Dixit

Director

CARE Ratings Limited

Phone: 91-120-4452002

E-mail: gaurav.dixit@careedge.in

Sudam Shrikrushna Shingade

Associate Director

CARE Ratings Limited

Phone: 912267543453

E-mail: sudam.shingade@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,
please visit www.careedge.in**